Cytokine dysregulation, inflammation and well-being

NeuroImmunoModulation

Volumn 12, Issue 5, 2005, Pages 255-269

  Elenkov, Ilia J ^a,d   Iezzoni, Domenic G ^b   Daly, Adrian ^e   Harris, Alan G ^b   Chrousos, George P ^c  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d Scientific Institute   (Italy)

^e UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Autoimmune diseases; Cytokines; Inflammation; Interleukins; Stress; Tumor necrosis factor

Indexed keywords

ADENOSINE; ADENOSINE TRIPHOSPHATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; C REACTIVE PROTEIN; CATECHOLAMINE DERIVATIVE; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; GLUCOCORTICOID; HISTAMINE; HYDROCORTISONE; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 8; INTERLEUKIN DERIVATIVE; METHYLPREDNISOLONE; SUBSTANCE P; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADRENERGIC SYSTEM; ADULT RESPIRATORY DISTRESS SYNDROME; ALLERGIC ASTHMA; ALLERGY; ATHEROSCLEROSIS; ATOPY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BEHAVIOR; CARDIOVASCULAR SYSTEM; CHOLINERGIC SYSTEM; CYTOKINE PRODUCTION; HELPER CELL; HOMEOSTASIS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE RESPONSE; IMMUNE SYSTEM; INFECTION; INFLAMMATION; MAJOR DEPRESSION; MAST CELL; METABOLIC SYNDROME X; NEUROENDOCRINE SYSTEM; OBESITY; PAIN; PATHOGENESIS; PEPTIDERGIC NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN SYNTHESIS; QUALITY OF LIFE; REVIEW; SENSORY NERVE; SEPSIS; SLEEP DISORDER; STRESS; TH1 CELL; TH2 CELL; WELLBEING;

ANIMALS; AUTOIMMUNE DISEASES; BRAIN; CYTOKINES; HOMEOSTASIS; HUMANS; INFLAMMATION; NEUROIMMUNOMODULATION;

EID: 24944580833     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087104     Document Type: Review

References (146)

1. Mosmann TR, Sad S: The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:138-146.
2. Fearon DT, Locksley RM: The instructive role of innate immunity in the acquired immune response. Science 1996;272:50-53.
3. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-146.
4. Humbert M, Menz G, Ying S, Corrigan CJ, Robinson DS, Durham SR, et al: The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: More similarities than differences. Immunol Today 1999;20:528-533.
5. Wills-Karp M: IL-12/IL-13 axis in allergic asthma. J Allergy Clin Immunol 2001;107:9-18.
6. Prussin C, Metcalfe DD: 4. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2003;111:S486-S494.
7. Taylor ML, Metcalfe DD: Mast cells in allergy and host defense. Allergy Asthma Proc 2001;22:115-119.
8. Metcalfe DD, Baram D, Mekori YA: Mast cells. Physiol Rev 1997;77:1033-1079.
9. Ricca V, Landi M, Ferrero P, Bairo A, Tazzer C, Canonica GW, et al: Minimal persistent inflammation is also present in patients with seasonal allergic rhinitis. J Allergy Clin Immunol 2000;105:54-57.
10. Ciprandi G, Buscaglia S, Pesce G, Pronzato C, Ricca V, Parmiani S, et al: Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. J Allergy Clin Immunol 1995;96:971-979.
11. Johnston SL, Pattemore PK, Sanderson G, Smith S, Campbell MJ, Josephs LK, et al: The relationship between upper respiratory infections and hospital admissions for asthma: A time-trend analysis. Am J Respir Crit Care Med 1996;154:654-660.
12. Naseer T, Minshall EM, Leung DY, Laberge S, Ernst P, Martin RJ, et al: Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy. Am J Respir Crit Care Med 1997;155:845-851.
13. Segal BM, Dwyer BK, Shevach EM: An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med 1998;187:537-546.
14. Bouma G, Strober W: The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3:521-533.
15. Strober W, Fuss I, Kitani A: Regulation of experimental mucosal inflammation. Acta Odontol Scand 2001;59:244-247.
16. Fuss IJ, Marth T, Neurath MF, Pearlstein GR, Jain A, Strober W: Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 1999;117:1078-1088.
17. Kronfol Z, Remick DG: Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000;157:683-694.
18. Corcos M, Guilbaud O, Hjalmarsson L, Chambry J, Jeammet P: Cytokines and depression: an analogic approach. Biomed Pharmacother 2002;56:105-110.
19. Wichers M, Maes M: The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 2002;5:375-388.
20. Greaves DR, Channon KM: Inflammation and immune responses in atherosclerosis. Trends Immunol 2002;23:535-541.
21. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-150.
22. Baeuerle PA, Baltimore D: Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-kappa B transcription factor. Cell 1988;53:211-217.
23. Meduri GU, Tolley EA, Chrousos GP, Stentz F: Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am J Respir Crit Care Med 2002;165:983-991.
24. Stentz F, Tolley E, Chrousos G, Meduri GU: Mechanisms of NF-κB and glucocorticoid receptors in activation and regulation of systemic inflammation in ARDS. Am J Respir Crit Care Med 2001;163:A450.
25. Elenkov IJ, Chrousos GP: Stress hormones, Th1/Th2 patterns, pro/anti-inflammatory cytokines and susceptibility to disease. Trends Endocrinol Metab 1999;10:359-368.
26. Elenkov IJ, Papanicolaou DA, Wilder RL, Chrousos GP: Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications. Proc Assoc Am Physicians 1996;108:374-381.
27. Panina-Bordignon P, Mazzeo D, Lucia PD, D'Ambrosio D, Lang R, Fabbri L, et al: Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest 1997;100:1513-1519.
28. Hasko G, Szabo C, Nemeth ZH, Salzman AL, Vizi ES: Stimulation of beta-adrenoceptors inhibits endotoxin-induced IL-12 production in normal and IL-10 deficient mice. J Neuroimmunol 1998;88:57-61.
29. Blotta MH, DeKruyff RH, Umetsu DT: Corticosteroids inhibit IL-12 production in human monocytes and enhance their capacity to induce IL-4 synthesis in CD4+ lymphocytes. J Immunol 1997;158:5589-5595.
30. DeKruyff RH, Fang Y, Umetsu DT: Corticosteroids enhance the capacity of macrophages to induce Th2 cytokine synthesis in CD4+ lymphocytes by inhibiting IL-12 production. J Immunol 1998;160:2231-2237.
31. Wu CY, Wang K, McDyer JF, Seder RA: Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. J Immunol 1998;161:2723-2730.
32. Ramierz F, Fowell DJ, Puklavec M, Simmonds S, Mason D: Glucocorticoids promote a TH2 cytokine response by CD4+ T cells in vitro. J Immunol 1996;156:2406-2412.
33. van der Poll T, Barber AE, Coyle SM, Lowry SF: Hypercortisolemia increases plasma interleukin-10 concentrations during human endotoxemia - a clinical research center study. J Clin Endocrinol Metab 1996;81:3604-3606.
34. Hetier E, Ayala J, Bousseau A, Prochiantz A: Modulation of interleukin-1 and tumor necrosis factor expression by beta-adrenergic agonists in mouse ameboid microglial cells. Exp Brain Res 1991;86:407-413.
35. Severn A, Rapson NT, Hunter CA, Liew FY: Regulation of tumor necrosis factor production by adrenaline and β-adrenergic agonists. J Immunol 1992;148:3441-3445.
36. Nakamura A, Johns EJ, Imaizumi A, Abe T, Kohsaka T: Regulation of tumour necrosis factor and interleukin-6 gene transcription by beta2-adrenoceptor in the rat astrocytes. J Neuroimmunol 1998;88:144-153.
37. Koff WC, Fann AV, Dunegan MA, Lachman LB: Catecholamine-induced suppression of interleukin-1 production. Lymphokine Res 1986;5:239-247.
38. van der Poll T, Lowry SF: Epinephrine inhibits endotoxin-induced IL-1 beta production: roles of tumor necrosis factor-alpha and IL-10. Am J Physiol 1997;273:R1885-R1890.
39. Sanders VM, Baker RA, Ramer-Quinn DS, Kasprowicz DJ, Fuchs BA, Street NE: Differential expression of the beta2-adrenergic receptor by Th1 and Th2 clones: implications for cytokine production and B cell help. J Immunol 1997;158:4200-4210.
40. Borger P, Hoekstra Y, Esselink MT, Postma DS, Zaagsma J, Vellenga E, et al: Beta-adrenoceptor-mediated inhibition of IFN-gamma, IL-3, and GM-CSF mRNA accumulation in activated human T lymphocytes is solely mediated by the beta2-adrenoceptor subtype. Am J Respir Cell Mol Biol 1998;19:400-407.
41. van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF: Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 1996;97:713-719.
42. Norris JG, Benveniste EN: Interleukin-6 production by astrocytes: induction by the neurotransmitter norepinephrine. J Neuroimmunol 1993;45:137-145.
43. Maimone D, Cioni C, Rosa S, Macchia G, Aloisi F, Annunziata P: Norepinephrine and vasoactive intestinal peptide induce IL-6 secretion by astrocytes: synergism with IL-1 beta and TNF alpha. J Neuroimmunol 1993;47:73-81.
44. Hasko G, Kuhel DG, Salzman AL, Szabo C: ATP suppression of interleukin-12 and tumour necrosis factor-alpha release from macrophages. Br J Pharmacol 2000;129:909-914.
45. Wilkin F, Stordeur P, Goldman M, Boeynaems JM, Robaye B: Extracellular adenine nucleotides modulate cytokine production by human monocyte-derived dendritic cells: dual effect on IL-12 and stimulation of IL-10. Eur J Immunol 2002;32:2409-2417.
46. la Sala A, Ferrari D, Corinti S, Cavani A, Di Virgilio F, Girolomoni G: Extracellular ATP induces a distorted maturation of dendritic cells and inhibits their capacity to initiate Th1 responses. J Immunol 2001;166:1611-1617.
47. Perregaux DG, McNiff P, Laliberte R, Conklyn M, Gabel CA: ATP acts as an agonist to promote stimulus-induced secretion of IL-1 beta and IL-18 in human blood. J Immunol 2000;165:4615-4623.
48. Chakfe Y, Seguin R, Antel JP, Morissette C, Malo D, Henderson D, et al: ADP and AMP induce interleukin-1beta release from microglial cells through activation of ATP-primed P2X7 receptor channels. J Neurosci 2002;22:3061-3069.
49. Cronstein BN, Naime D, Ostad E: The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92:2675-2682.
50. Cronstein BN, Rosenstein ED, Kramer SB, Weissmann G, Hirschhorn R: Adenosine; a physiologic modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on human neutrophils. J Immunol 1985;135:1366-1371.
51. Lappin D, Riches DW, Damerau B, Whaley K: Cyclic nucleotides and their relationship to complement-component-C2 synthesis by human monocytes. Biochem J 1984;222:477-486.
52. Link AA, Kino T, Worth JA, McGuire JL, Crane ML, Chrousos GP, et al: Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes. J Immunol 2000;164:436-442.
53. Prabhakar U, Brooks DP, Lipshlitz D, Esser KM: Inhibition of LPS-induced TNF alpha production in human monocytes by adenosine (A2) receptor selective agonists. Int J Immunopharmacol 1995;17:221-224.
54. Le Moine O, Stordeur P, Schandene L, Marchant A, de Groote D, Goldman M, et al: Adenosine enhances IL-10 secretion by human monocytes. J Immunol 1996;156:4408-4414.
55. Hasko G, Szabo C, Nemeth ZH, Kvetan V, Pastores SM, Vizi ES: Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol 1996;157:4634-4640.
56. Falus A, Meretey K: Histamine: an early messenger in inflammatory and immune reactions. Immunol Today 1992;13:154-156.
57. Vannier E, Miller LC, Dinarello CA: Histamine suppresses gene expression and synthesis of tumor necrosis factor alpha via histamine H2 receptors. J Exp Med 1991;174:281-284.
58. Vannier E, Dinarello CA: Histamine enhances interleukin (IL)-1-induced IL-6 gene expression and protein synthesis via H2 receptors in peripheral blood mononuclear cells. J Biol Chem 1994;269:9952-9956.
59. Elenkov IJ, Webster E, Papanicolaou DA, Fleisher TA, Chrousos GP, Wilder RL: Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors. J Immunol 1998;161:2586-2593.
60. Idzko M, la Sala A, Ferrari D, Panther E, Herouy Y, Dichmann S, et al: Expression and function of histamine receptors in human monocyte-derived dendritic cells. J Allergy Clin Immunol 2002;109:839-846.
61. Lagier B, Lebel B, Bousquet J, Pene J: Different modulation by histamine of IL-4 and interferon-gamma (IFN-γ) release according to the phenotype of human Th0, Th1 and Th2 clones. Clin Exp Immunol 1997;108:545-551.
62. Lotz M, Vaughan JH, Carson DA: Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science 1988;241:1218-1221.
63. Kincy-Cain T, Bost KL: Substance P-induced IL-12 production by murine macrophages. J Immunol 1997;158:2334-2339.
64. Ho WZ, Stavropoulos G, Lai JP, Hu BF, Magafa V, Anagnostides S, et al: Substance P C-terminal octapeptide analogues augment tumor necrosis factor-alpha release by human blood monocytes and macrophages. J Neuroimmunol 1998;82:126-132.
65. Fox FE, Kubin M, Cassin M, Niu Z, Hosoi J, Torii H, et al: Calcitonin gene-related peptide inhibits proliferation and antigen presentation by human peripheral blood mononuclear cells: effects on B7, interleukin 10, and interleukin 12. J Invest Dermatol 1997;108:43-48.
66. Liu J, Chen M, Wang X: Calcitonin gene-related peptide inhibits lipopolysaccharide-induced interleukin-12 release from mouse peritoneal macrophages, mediated by the cAMP pathway. Immunology 2000;101:61-67.
67. Ganea D, Delgado M: Inhibitory neuropeptide receptors on macrophages. Microbes Infect 2001;3:141-147.
68. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, et al: Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000;405:458-462.
69. Tracey KJ: The inflammatory reflex. Nature 2002;420:853-859.
70. Bentley AM, Hamid Q, Robinson DS, Schotman E, Meng Q, Assoufi B, et al: Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am J Respir Crit Care Med 1996;153:551-556.
71. Bradding P, Feather IH, Wilson S, Holgate ST, Howarth PH: Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid. Am J Respir Crit Care Med 1995;151:1900-1906.
72. Batuman OA, Ferrero A, Cupp C, Jimenez SA, Khalili K: Differential regulation of transforming growth factor beta-1 gene expression by glucocorticoids in human T and glial cells. J Immunol 1995;155:4397-4405.
73. Broug-Holub E, Kraal G: Dose- and time-dependent activation of rat alveolar macrophages by glucocorticoids. Clin Exp Immunol 1996;104:332-336.
74. Spengler RN, Allen RM, Remick DG, Stricter RM, Kunkel SL: Stimulation of α-adrenergic receptor augments the production of macrophage-derived tumor necrosis factor. J Immunol 1990;145:1430-1434.
75. Le Tulzo Y, Shenkar R, Kaneko D, Moine P, Fantuzzi G, Dinarello CA, et al: Hemorrhage increases cytokine expression in lung mononuclear cells in mice: involvement of catecholamines in nuclear factor-κB regulation and cytokine expression. J Clin Invest 1997;99:1516-1524.
76. Broug-Holub E, Persoons JH, Schornagel K, Mastbergen SC, Kraal G: Effects of stress on alveolar macrophages: a role for the sympathetic nervous system. Am J Respir Cell Mol Biol 1998;19:842-848.
77. Kavelaars A, van de Pol M, Zijlstra J, Heijnen CJ: Beta 2-adrenergic activation enhances interleukin-8 production by human monocytes. J Neuroimmunol 1997;77:211-216.
78. Linden A: Increased interleukin-8 release by beta-adrenoceptor activation in human transformed bronchial epithelial cells. Br J Pharmacol 1996;119:402-406.
79. Engstad CS, Lund T, Osterud B: Epinephrine promotes IL-8 production in human leukocytes via an effect on platelets. Thromb Haemost 1999;81:139-145.
80. Kaplanski G, Porat R, Aiura K, Erban JK, Gelfand JA, Dinarello CA: Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1-mediated event. Blood 1993;81:2492-2495.
81. Mohamed-Ali V, Flower L, Sethi J, Hotamisligil G, Gray R, Humphries SE, et al: Beta-adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies. J Clin Endocrinol Metab 2001;86:5864-5869.
82. Vicennati V, Vottero A, Friedman C, Papanicolaou DA: Hormonal regulation of interleukin-6 production in human adipocytes. Int J Obes Relat Metab Disord 2002;26:905-911.
83. Baumann H, Gauldie J: The acute phase response. Immunol Today 1994;15:74-80.
84. Li Y, Chi L, Stechschulte DJ, Dileepan KN: Histamine-induced production of interleukin-6 and interleukin-8 by human coronary artery endothelial cells is enhanced by endotoxin and tumor necrosis factor-alpha. Microvasc Res 2001;61:253-262.
85. Murray DR, Prabhu SD, Chandrasekar B: Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 2000;101:2338-2341.
86. Karalis K, Sano H, Redwine J, Listwak S, Wilder RL, Chrousos GP: Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science 1991;254:421-423.
87. Elenkov IJ, Webster EL, Torpy DJ, Chrousos GP: Stress, corticotropin-releasing hormone, glucocorticoids, and the immune/inflammatory response: acute and chronic effects. Ann NY Acad Sci 1999;876:1-11.
88. Theoharides TC, Singh LK, Boucher W, Pang X, Letourneau R, Webster E, et al: Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology 1998;139:403-413.
89. Foreman JC: Substance P and calcitonin gene-related peptide: effects on mast cells and in human skin. Int Arch Allergy Appl Immunol 1987;82:366-371.
90. Church MK, Lowman MA, Robinson C, Holgate ST, Benyon RC: Interaction of neuropeptides with human mast cells. Int Arch Allergy Appl Immunol 1989;88:70-78.
91. Theoharides TC, Spanos C, Pang X, Alferes L, Ligris K, Letourneau R, et al: Stress-induced intracranial mast cell degranulation: a corticotropin- releasing hormone-mediated effect. Endocrinology 1995;136:5745-5750.
92. Chrousos GP: The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation (see comments). N Engl J Med 1995;332:1351-1362.
93. Chrousos GP: Stressors, stress, and neuroendocrine integration of the adaptive response. The 1997 Hans Selye Memorial Lecture. Ann NY Acad Sci 1998;851:311-335.
94. Clauw DJ, Chrousos GP: Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation 1997;4:134-153.
95. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP: The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998;128:127-137.
96. Crofford LJ, Kalogeras KT, Mastorakos G, Magiakou MA, Wells J, Kanik KS, et al: Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J Clin Endocrinol Metab 1997;82:1279-1283.
97. Vgontzas AN, Papanicolaou DA, Bixler EO, Lotsikas A, Zachman K, Kales A, et al: Circadian interleukin-6 secretion and quantity and depth of sleep. J Clin Endocrinol Metab 1999;84:2603-2607.
98. Vgontzas AN, Papanicolaou DA, Bixler EO, Hopper K, Lotsikas A, Lin HM, et al: Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000;85:1151-1158.
99. Vgontzas AN, Zoumakis M, Papanicolaou DA, Bixler EO, Prolo P, Lin HM, et al: Chronic insomnia is associated with a shift of interleukin-6 and tumor necrosis factor secretion from nighttime to daytime. Metabolism 2002;51:887-892.
100. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP: Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab 1997;82:1313-1316.
101. Marshall GD Jr, Agarwal SK: Stress, immune regulation, and immunity: applications for asthma. Allergy Asthma Proc 2000;21:241-246.
102. von Hertzen LC: Maternal stress and T-cell differentiation of the developing immune system: possible implications for the development of asthma and atopy. J Allergy Clin Immunol 2002;109:923-928.
103. Barnes P, FitzGerald G, Brown M, Dollery C: Nocturnal asthma and changes in circulating epinephrine, histamine, and cortisol. N Engl J Med 1980;303:263-267.
104. 2-Agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest 1997;100:1513-1519.
105. Zieg G, Lack G, Harbeck RJ, Gelfand EW, Leung DY: In vivo effects of glucocorticoids on IgE production (see comments). J Allergy Clin Immunol 1994;94:222-230.
106. Coqueret O, Lagente V, Frere CP, Braquet P, Mencia-Huerta JM: Regulation of IgE production by beta 2-adrenoceptor agonists. Ann NY Acad Sci 1994;725:44-49.
107. Sternberg EM: Neuroendocrine regulation of autoimmune/inflammatory disease. J Endocrinol 2001;169:429-435.
108. Elenkov IJ, Chrousos GP: Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann NY Acad Sci 2002;966:290-303.
109. Sternberg EM, Young WS, Bernardini R, Calogero AE, Chrousos GP, Gold PW, et al: A central nervous system defect in biosynthesis of corticotropin- releasing hormone is associated with susceptibility to streptococcal cell wall-induced arthritis in Lewis rats. Proc Natl Acad Sci USA 1989;86:4771-4775.
110. Sternberg EM, Hill JM, Chrousos GP, Kamilaris T, Listwak SJ, Gold PW, et al: Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats. Proc Natl Acad Sci USA 1989;86:2374-2378.
111. Wilder RL: Neuroendocrine-immune system interactions and autoimmunity. Annu Rev Immunol 1995;13:307-338.
112. Wilder RL, Elenkov IJ: Hormonal regulation of tumor necrosis factor-alpha, interleukin-12 and interleukin-10 production by activated macrophages. A disease-modifying mechanism in rheumatoid arthritis and systemic lupus erythematosus? Ann NY Acad Sci 1999;876:14-31.
113. Straub RH, Cutolo M: Involvement of the hypothalamic-pituitary-adrenal/ gonadal axis and the peripheral nervous system in rheumatoid arthritis: viewpoint based on a systemic pathogenetic role. Arthritis Rheum 2001;44:493-507.
114. Karaszewski JW, Reder AT, Maselli R, Brown M, Arnason BG: Sympathetic skin responses are decreased and lymphocyte beta-adrenergic receptors are increased in progressive multiple sclerosis. Ann Neurol 1990;27:366-372.
115. Arnason BG, Brown M, Maselli R, Karaszewski J, Reder A: Blood lymphocyte beta-adrenergic receptors in multiple sclerosis. Ann NY Acad Sci 1988;540:585-588.
116. Karaszewski JW, Reder AT, Anlar B, Arnason GW: Increased high affinity beta-adrenergic receptor densities and cyclic AMP responses of CD8 cells in multiple sclerosis. J Neuroimmunol 1993;43:1-7.
117. Arnason BG, Noronha AB, Reder AT: Immunoregulation in rapidly progressive multiple sclerosis. Ann NY Acad Sci 1988;540:4-12.
118. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES: The sympathetic nerve - an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 2000;52:595-638.
119. Miller LE, Justen HP, Scholmerich J, Straub RH: The loss of sympathetic nerve fibers in the synovial tissue of patients with rheumatoid arthritis is accompanied by increased norepinephrine release from synovial macrophages. FASEB J 2000;14:2097-2107.
120. Elenkov LT, Wilder RL, Bakalov VK, Link AA, Dimitrov MA, Fisher S, et al: IL-12, TNF-alpha, and hormonal changes during late pregnancy and early postpartum: implications for autoimmune disease activity during these times. J Clin Endocrinol Metab 2001;86:4933-4938.
121. Wong ML, Kling MA, Munson PJ, Listwak S, Licinio J, Prolo P, et al: Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci USA 2000;97:325-330.
122. Gold PW, Chrousos GP: The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences. Proc Assoc Am Physicians 1999;111:22-34.
123. Gold PW, Chrousos GP: Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs. low CRH/NE states. Mol Psychiatry 2002;7:254-275.
124. Jarek MJ, Legare EJ, McDermott MT, Merenich JA, Kollef MH: Endocrine profiles for outcome prediction from the intensive care unit. Crit Care Med 1993;21:543-550.
125. Rothwell PM, Lawler PG: Prediction of outcome in intensive care patients using endocrine parameters (see comments). Crit Care Med 1995;23:78-83.
126. Munford RS, Tracey KJ: Is severe sepsis a neuroendocrine disease? Mol Med 2002;8:437-442.
127. O'Sullivan ST, Lederer JA, Horgan AF, Chin DH, Mannick JA, Rodrick ML: Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection (see comments). Ann Surg 1995;222:482-490.
128. Brune IB, Wilke W, Hensler T, Holzmann B, Siewert JR: Downregulation of T helper type 1 immune response and altered pro-inflammatory and anti-inflammatory T cell cytokine balance following conventional but not laparoscopic surgery. Am J Surg 1999;177:55-60.
129. Woiciechowsky C, Asadullah K, Nestler D, Eberhardt B, Platzer C, Schoning B, et al: Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury (in process citation). Nat Med 1998;4:808-813.
130. Franchimont D, Kino T, Galon J, Meduri GU, Chrousos G: Glucocorticoids and inflammation revisited: the state of the art. NIH Clinical Staff Conference. Neuroimmunomodulation 2003;10:247-260.
131. Minneci PC, Deans KJ, Banks SM, Eichacker PQ, Natanson C. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 2004;141:47-56.
132. Meduri GU, Chrousos GP: Duration of glucocorticoid treatment and outcome in sepsis: is the right drug used the wrong way? Chest 1998;114:355-360.
133. Meduri GU, Kanangat S: Glucocorticoid treatment of sepsis and acute respiratory distress syndrome: time for a critical reappraisal. Crit Care Med 1998;26:630-633.
134. Meduri GU: New rationale for glucocorticoid treatment in septic shock. J Chemother 1999;11:541-550.
135. Altare F, Durandy A, Lammas D, Emile JF, Lamhamedi S, Le Deist F, et al: Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998;280:1432-1435.
136. Lerner BH: Can stress cause disease? Revisiting the tuberculosis research of Thomas Holmes, 1949-1961. Ann Intern Med 1996;124:673-680.
137. Levenstein S, Ackerman S, Kiecolt-Glaser JK, Dubois A: Stress and peptic ulcer disease. JAMA 1999;281:10-11.
138. Cohen S, Tyrrell DA, Smith AP: Psychological stress and susceptibility to the common cold (see comments). N Engl J Med 1991;325:606-612.
139. Cole SW, Korin YD, Fahey JL, Zack JA: Norepinephrine accelerates HIV replication via protein kinase A-dependent effects on cytokine production. J Immunol 1998;161:610-616.
140. Cole SW, Naliboff BD, Kemeny ME, Griswold MP, Fahey JL, Zack JA: Impaired response to HAART in HIV-infected individuals with high autonomic nervous system activity. Proc Natl Acad Sci USA 2001;98:12695-12700.
141. Kino T, Gragerov A, Kopp JB, Stauber RH, Pavlakis GN, Chrousos GP: The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor (in process citation). J Exp Med 1999;189:51-62.
142. Mirani M, Elenkov I, Volpi S, Hiroi N, Chrousos GP, Kino T: HIV-1 protein Vpr suppresses IL-12 production from human monocytes by enhancing glucocorticoid action: potential implications of Vpr coactivator activity for the innate and cellular immunity deficits observed in HIV-1 infection. J Immunol 2002;169:6361-6368.
143. Rook GA, Lightman SL, Heijnen CJ: Can nerve damage disrupt neuroendocrine immune homeostasis? Leprosy as a case in point. Trends Immunol 2002;23:18-22.
144. Black PH: Stress and the inflammatory response: a review of neurogenic inflammation. Brain Behav Immun 2002;16:622-653.
145. Black PH, Garbutt LD: Stress, inflammation and cardiovascular disease. J Psychosom Res 2002;52:1-23.
146. Elenkov IJ: Neuroendocrine effects on immune system; in DeGroot L, Chrousos GP (eds): www.endotext.com/ (online Endocrine Source). 2003.